Saturday, December 10, 2016 3:51:55 AM
As an aside, the article mentions that a strong influx of Ca2+ into the mitochondria for a prolonged length of time can actually cause cell death! 273's affinity and bond to the sigma 1 receptor must be just right to trigger the release of just the precise amount of Ca2+ from the ER into the mitochondria. The amount and rate of Ca2+ flowing into the mitochondria produces different signals for the cell to carry out. The flow of Ca2+ initiated by 273 signals the mitochondria to generate the required amount of ATP needed to restore homeostasis. I've read elsewhere that agonists of receptors can have too low an affinity or too high an affinity for receptors to be of much benefit, or their action may actually harm the cell. Imagine an agonist of very high affinity binding to the sigma 1 receptor. It's gonna have a strong, persistent affect on that receptor. If the receptor is a sigma 1 on the ER, A LOT of Ca2+ is gonna flow from the ER to the mitochondria for a long time. If that flow is too strong and for too long, that will not send the proper signal to the mitochondria to restore homeostasis. In fact, it might even signal the cell to self destruct (apoptosis). Not good. Donepezil has a very high affinity for sigma 1, probably too high to send the correct signal to the mitochondria.
"The ability of mitochondria to capture Ca2+ ions has important functional implications for cells, because mitochondria shape cellular Ca2+ signals by acting as a Ca2+ buffer and respond to Ca2+ elevations either by increasing the cell energy supply or by triggering the cell death program of apoptosis. A mitochondrial Ca2+ channel known as the uniporter drives the rapid and massive entry of Ca2+ ions into mitochondria.
The net result of the increase in [Ca2+]mit is to increase the respiratory rate, H+ extrusion and ATP production. The [Ca2+]mit dependency of mitochondrial bioenergetics enables mitochondria to decode Ca2+ signals, and thus to tune ATP synthesis to the energetic requirements of the cell [9], [10] and [11]. However, prolonged increases in [Ca2+]mit can induce the opening of the mitochondrial permeability transition pore (PTP) leading to mitochondrial swelling, cytochrome C release, and cell death by apoptosis [12] and [13].
...the central role played by two organelles in cellular Ca2+ homeostasis: the endoplasmic reticulum (ER) and mitochondria. The ER is the major intracellular Ca2+ stores of cells, whereas mitochondria shape and decode cellular Ca2+ signals by taking up and then releasing Ca2+ ions. The Ca2+ uptake mechanisms of mitochondria have attracted much attention recently, due to the central role of mitochondria in cell metabolism and cell death.
Functional and morphological evidence indicate that mitochondria are in close contacts with the endoplasmic reticulum (ER) and with cell membrane channels [33]. The close contacts between the ER and mitochondria have received much attention, and several proteins have been proposed to link mitochondria to the ER."
http://www.sciencedirect.com/science/article/pii/S0005272810005797
Recent AVXL News
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM